NCT05945524 Analysis of the Resistance and Sensitivity Mechanisms to Teclistamab by Focusing on Single Immune Cell Examination
| NCT ID | NCT05945524 |
| Status | Recruiting |
| Phase | — |
| Sponsor | University Hospital, Toulouse |
| Condition | Multiple Myeloma |
| Study Type | INTERVENTIONAL |
| Enrollment | 100 participants |
| Start Date | 2023-09-28 |
| Primary Completion | 2026-03-31 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 100 participants in total. It began in 2023-09-28 with a primary completion date of 2026-03-31.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The aim of this study is to discover the immune and oncogenomic features that distinguish patients who respond to teclistamab from patients who are primarily resistant. Moreover, phenotypic and genotypic characteristics that occur with secondary resistance to teclistamab will be analyzed.
Eligibility Criteria
Inclusion Criteria: * With multiple myeloma * Who receive Teclistamab * Consent form signed Exclusion Criteria: * Patient under legal protection
Contact & Investigator
Hervé AVET LOISEAU, MD, PhD
PRINCIPAL INVESTIGATOR
University Hospital, Toulouse
Frequently Asked Questions
Who can join the NCT05945524 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Multiple Myeloma. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT05945524 currently recruiting?
Yes, NCT05945524 is actively recruiting participants. Contact the research team at avetloiseau.herve@iuct-oncopole.fr for enrollment information.
Where is the NCT05945524 trial being conducted?
This trial is being conducted at Amiens, France, Caen, France, Dijon, France, Epagny Metz- Tessy, France and 11 additional locations.
Who is sponsoring the NCT05945524 clinical trial?
NCT05945524 is sponsored by University Hospital, Toulouse. The principal investigator is Hervé AVET LOISEAU, MD, PhD at University Hospital, Toulouse. The trial plans to enroll 100 participants.